RJA
CUE icon

Raymond James & Associates’s Cue Biopharma CUE Stock Holding History

Raymond James & Associates’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,260
Closed -$292K – 3663
2019
Q1 		$292K Buy
+1,260
New +$240K ﹤0.01% 2994

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Raymond James & Associates's CUE Position: Q2 2019 in Review

Raymond James & Associates sold out of Cue Biopharma (CUE) in Q2 2019, closing a stake of 1,260 shares — an estimated $292K sold.

Raymond James & Associates first reported a position in CUE in Q1 2019 and held it in 1 quarter. The position peaked at $292K in Q1 2019. 37 funds tracked by Wall St. Rank hold CUE as of Q2 2019.

  • Raymond James & Associates reported no remaining Cue Biopharma position as of Q2 2019 after selling out during the quarter.
  • Raymond James & Associates sold 1,260 Cue Biopharma shares in Q2 2019, an estimated $292K.
  • Raymond James & Associates first reported a position in Cue Biopharma in Q1 2019 and held it in 1 quarter.
  • Raymond James & Associates's Cue Biopharma position peaked at $292K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.